Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Core Insights - Rigel Pharmaceuticals is set to present data from its hematology-oncology portfolio at the 66th American Society of Hematology (ASH) Annual Meeting from December 7-10, 2024, in San Diego, California [1][2] Group 1: R289 Study - Initial data from the Phase 1b study of R289, a dual IRAK1/4 inhibitor, shows it was well tolerated in heavily pretreated patients with lower-risk myelodysplastic syndrome (LR-MDS), with a median of 4 prior therapies [3][4] - Among 14 evaluable patients, 36% achieved RBC-transfusion independence or hematologic improvement with a median duration of 29 weeks [3][4] Group 2: Olutasidenib Data - Data on olutasidenib for relapsed/refractory mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML) indicates that some patients respond quickly within 1-2 months, while others may take up to 10 months for overall response [3][4] - A combination of olutasidenib and azacitidine achieved a complete remission or complete remission with partial hematologic recovery in 31% of patients, with a median duration of 15 months [4][5] - In a study comparing olutasidenib to ivosidenib, olutasidenib showed favorable effectiveness in patients with mIDH1 AML who were relapsed or refractory to a venetoclax-based regimen [6] Group 3: TAVALISSE Data - TAVALISSE (fostamatinib) is indicated for chronic immune thrombocytopenia (ITP) and has shown clinically meaningful responses in combination with thrombopoietin receptor agonists [7][8] - The safety profile of TAVALISSE includes monitoring for hypertension and elevated liver function tests, with diarrhea occurring in 31% of patients [7][8]